
ABOUT ALTASCIENCES
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.
FEATURED CONTENT
-
Given its close physiological similarities to humans, the minipig should be considered a valuable alternative for nonclinical safety assessments in small molecule and biologic drug development.
-
Discover the benefits of liquid-filled capsules for efficient, scalable, and patient-friendly drug manufacturing, and how they can enhance bioavailability and simplify complex formulations.
-
Discover why gathering and analyzing pharmacokinetic (PK) and pharmacodynamic (PD) data is key — from preclinical studies right to clinical trial conduct.
-
Discover how nanomilling, a game-changing technique that tackles poor solubility and bioavailability in drug development, can optimize your drug’s formulation.
-
Learn how formulation development drives every phase of early drug development ― from concept to clinic. It ensures precise dosing, stability, and safety while providing critical data for regulatory submissions.
-
Explore how comprehensive API testing can optimize drug formulation and enhance bioavailability to ensure the success of your pharmaceutical products.
-
Liquid-filled, two-piece capsules offer significant advantages over traditional solid dosage forms. Here, we review the five reasons liquid-filled capsules (LFCs) can benefit your clinical trials.
-
Understand how early engagement with a fully integrated and experienced CNS drug development partner can accelerate timelines by facilitating continuous data sharing and decision-making.
-
Liquid-filled hard-shell capsules offer these indisputable advantages in each phase of drug development.
-
Dive into each service Altasciences provides as it relates to drug development for small molecules, elucidating how they can support and guide teams at every step.
FEATURED WEBINARS
-
Learn about key topics in nanomilling, including practical applications and advantages, specialized equipment, milling media, stabilizers, as well as manufacturing and scale-up considerations.
-
Take proactive steps to ensure compliance and optimize efficiency in pharmaceutical manufacturing by exploring the benefits of terminal sterilization for your drug products today.
-
Discover the advantages of LFHCs, including improved solubility and bioavailability, enhanced stability, and customizable release profiles, and how they can accelerate drug development timelines.
-
Learn how CROs and CDMOs work in tandem to address operational and regulatory challenges for pharmaceutical and biotech companies, and how this can determine study success or failure.
-
Learn more about the benefits of nanomilling, types of milling media and stabilizers, and scale up for clinical manufacturing.
CONTACT INFORMATION
Altasciences
1510 Delp Drive
Harleysville, PA 19438
UNITED STATES
Contact: contact@altasciences.com
FEATURED SOLUTIONS
-
Liquid-filled, two-piece capsules offer several advantages over other solid dosage forms, such as ease of scalability and manufacturing, faster absorption, simpler packaging, and higher product stability. Liquid filling also offers the ability to control R&D compounds, which are expensive and in limited supply. They are also known to accelerate product development because they can be made with fewer excipients than other solid dosage forms, such as tablets.
-
Nanomilling revolutionizes drug delivery by reducing particle size to enhance solubility, bioavailability, and therapeutic efficacy, addressing the challenges of poorly water-soluble APIs.
-
There is a growing demand for the sterilization of small-molecule parenteral products, including heart medications, eye drops, analgesics, and antibiotics, as well as intravenous solutions, such as glucose, potassium, and saline. To ensure patient safety, these drug products and related instruments commonly used in hospitals must be thoroughly sterilized after being manufactured. Known as "terminal sterilization," this highly efficient process ensures that no microbial contaminants like fungi or bacteria are present when the product is used.
If you have a product that needs to be terminally sterilized, we can help.
-
Proper formulation of active pharmaceutical ingredients (APIs) is essential for achieving therapeutic efficacy, ensuring patient safety, maintaining product stability, optimizing pharmacokinetics, meeting regulatory requirements, and enhancing cost-effectiveness in pharmaceutical development.
-
Altasciences' manufacturing (CDMO) team provides tailored solutions for each phase of your drug development program. From discovery to market ― they’ve got you covered!
-
With our specialized support, you can be confident that your ophthalmic drug will not only meet regulatory standards but also address unmet medical needs in the most expedited manner possible.
-
Our approach is designed to optimize efficiency and accelerate timelines, resulting in up to 40% time savings throughout the early phases of your drug development journey.
-
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions support programs from lead candidate selection to market. You will benefit from working with a single partner as your product advances through each phase of drug development—from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in time savings.
-
Explore our collection of capabilities, including liquid-filled capsules, band/sealing technologies, powder, over-encapsulated capsules, topical formulations, and clinical and blister packaging.
-
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market.
FEATURED AUDIO
-
Drug development in the ocular space has specific challenges. Explore how an end-to-end solution can facilitate a path to Phase 2.